Abstract. Chemotherapy (CT) resistance in ovarian cancer is related to multiple factors, and assessment of these factors is necessary for the development of new drugs and therapeutic regimens. In an effort to identify such determinants, we evaluated the expression of approximately 21,000 genes using DNA microarray screening in paired tumor samples taken prior to and after CT treatment from 6 patients with predominantly advanced stage, high-grade epithelial ovarian cancer.
Introduction
Epithelial carcinoma of the ovary is characterized by presentation at an advanced stage and spreads primarily by an intraperitoneal route. An initial surgical approach is essential to proper staging of the disease process and to aggressive cytoreduction, which in turn improves response to chemotherapy and survival (1) . Chemotherapy (CT) has had an increasingly important role in the effective treatment of ovarian cancer. Combination CT with taxol plus a platinum compound (carboplatin or cisplatin) is the current regimen of choice for the treatment of advanced epithelial ovarian cancer (2) . A number of clinical issues, however, are unresolved including drug dosage and schedule, duration of treatment, and route of administration (3) . Thus, although significant proportions of women respond to CT, the majority of responders (~50-75%) eventually relapse at a median of 18-28 months (Du Bois A, et al, Proc ASCO 18: abs. 356, 1997; Ozols RF, et al, Proc ASCO 18: abs. 356, 1999) . Treatment decisions at this juncture include supplementary chemotherapy with topotecan, doxorubicin, hormones, surgery, and experimental agents (4) . Nonetheless, even with these additional treatments relapse rates remain high and most women with advanced ovarian cancer ultimately will die of their disease (5) .
CT resistance in ovarian cancer is broad and encompasses diverse unrelated drugs, suggesting more than one mechanism of resistance. This topic has been the subject of intense research, and previous studies on ovarian cancer chemoresistance have investigated potential involvement of molecules involved in drug transport, apoptosis, DNA repair, and detoxification pathways (6) (7) (8) (9) (10) . However for the majority of these factors, in vivo studies have failed to assess their clinical importance and to translate them into recommendations for specific therapies or prognosis in ovarian cancer patients (11) (12) (13) . The above investigations suggest that CT resistance in ovarian cancer is related to multiple factors, and assessment of these factors is necessary for the development of new drugs and therapeutic regimens. In an effort to identify such determinants, we evaluated the expression of ~21,000 genes using DNA microarray screening in paired tumor samples taken prior to and following CT treatment from six ovarian cancer patients. For each patient, the gene expression profile of the post-CT tumor was compared to that of the corresponding primary 'chemonaïve' tumor sample. Our results provide the basis for further extended validation of specific markers that may be involved in the molecular mechanisms of clinical multidrug resistance in ovarian cancer.
Patients and methods
Patients and tissue specimens. Cancer tissues taken prior to (primary tumor tissue), and after adjuvant CT, were obtained for expression profiling analysis from 6 ovarian cancer patients. Paired tumor samples (pre-and post-CT) from 5 patients were obtained from the ovarian tumor bank at the Cancer Research Center at the Hôtel-Dieu de Québec Hospital, Québec, Canada, and paired tumor samples from one additional ovarian cancer patient were obtained from the ovarian tumor bank at the Department of Pathology, Vancouver General Hospital, British Columbia Cancer Agency, Vancouver, Canada. All tumors were histologically classified and graded according to the criteria defined by the World Health Organization. Tumor material from all patients was snapfrozen in liquid nitrogen within 1 h after surgery. Frozen sections were stained with hematoxylin and eosin; only samples that had more than 70% tumor cells were selected. All patients provided informed consent for voluntary participation before any procedures.
Gene expression analysis. Total RNA was isolated from frozen primary ovarian tumor samples using the TRIzol reagent (Invitrogen, Burlington, ON, Canada) and finally dissolved in RNase-free H 2 O. Total RNA (5-10 μg) was treated with DNase using the RNase-free DNase kit and RNeasy spin columns (Qiagen, Mississauga, ON). Total RNA treated with DNase was dissolved in RNase-free H 2 O to a final concentration of 0.2-0.5 μg/μl. The quality of all RNA samples was examined by capillary electrophoresis using the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA). Fluorescently labeled cRNA targets were generated from 0.5 μg of total RNA in each reaction using the Fluorescent Linear Amplification Kit (Agilent) and 10.0 mM Cyanine 3-or 5-labeled CTP (Perkin-Elmer, Boston, MA), and following user's manual. Labeled cRNAs were purified using the RNeasy Mini Kit (Qiagen) and applied to the Human 1A (v2) Oligonucleotide Microarray (Agilent), containing 20,174 genes. For each patient, 1 μg of cyanine-labeled cRNA from the primary (pre-CT) tumor sample was mixed with equal amount of reverse-color cyanine labeled cRNA from the post-CT tumor sample. Hybridization and washing was performed using the in situ Hybridization Plus Kit (Agilent) and following the manufacturer's instructions. The arrays were scanned using a dual-laser DNA microarray scanner (Agilent). The data were then extracted from images by the Feature Extraction software 6.1 (Agilent). All microarray experiments were performed in duplicates.
Data analysis. The GeneSpring software (Agilent) was used to generate lists of selected genes and for different statistical and visualization methods. An Intensity-Dependent Normalization (known as Lowess normalization) was applied to correct for artifacts caused by non-linear rates of dye incorporation as well as inconsistencies of the relative fluorescence intensity between some red and green dyes. An initial gene list of 910 genes was created by Filtering on Confidence at p=0.05 (using as measure of confidence the t-test p-value, and as multiple testing correction -the Benjamini and Hochberg false discovery rate) to eliminate genes with unreliable measurements. Consecutive lists of differentially expressed genes derived from the 910 gene list were generated considering a 1.5-to 2-fold expression and using data from all independent experiments. Moreover, based on individual gene expression profiles, two distinct groups of patients were identified and the significant differences in expressed levels between the two groups were determined using 2-fold expression difference and the One-Way ANOVA test (Welch t-test) with p-value cutoff of 0.005. Comparisons of gene expression across the two groups were performed by Cluster Analysis using the Condition Tree Algorithm. The genes in the gene lists were classified according to their function using the Gene Ontology (GO SLIMS) classification system.
Semi-quantitative RT-PCR.
Validation of differential gene expression was performed for a number of genes that were differentially expressed between the pre-CT and the post-CT tumor samples in all 6 ovarian cancer patients. The actinregulatory protein cap G gene (CAPG) displayed no change in expression levels in all tumor samples analyzed and was used as an internal standard. Primers were designed for these loci with the sequences freely available from the Entrez Nucleotide database and the Primer3 algorithm for primer design (http://www-genome.wi.mit.edu/cgi-bin/primer/ primer3_www.cgi). After determination of correct cycling parameters in order to allow measurements in the exponential PCR phase, a duplex semi-quantitative RT-PCR (sqRT-PCR) was performed as previously described (14) . Briefly, 2 μg of DNase I-treated RNA was reverse-transcribed into first-strand cDNA in a 20-ml reaction using the MMLV (Moloney-murineleukaemia virus) RT (Invitrogen). cDNA templates (0.5 μg) were amplified in a 50-μl reaction containing 2.5 pmol of each primer, 200 mM dNTPs and 1.5 units of Taq polymerase (Invitrogen). Each PCR reaction contained two pairs of PCR primers needed for the simultaneous amplification of two PCR fragments: one belonging to the gene of interest and the other representing the CAPG PCR fragment, used as an internal standard. The samples were initially denatured for 3 min at 94˚C and then submitted to 21-25 cycles of PCR (45 sec at 94˚C, 45 sec at 58-62˚C and 75 sec at 72˚C) followed by a 10-min final elongation step at 72˚C. One-fifth of each PCR was run on a 1.5-2% agarose gel in 1X TBE buffer (45 mM Tris/borate/1 mM EDTA) and the gel was documented using the AlphaImager 2200 gel documentation system (Alpha Innotech, San Leandro, CA) and analyzed using the publicly available NIH ImageJ 1.33u program (http:// rsb.info.nih.gov/ij). Each expression value was calculated as a relative ratio between the signal of the specific PCR fragment and that of the internal standard. The data obtained were statistically analyzed by the unpaired t-test using the GraphPad InStat Software version 3.06 (San Diego, CA).
p53 gene mutation analysis. p53 mutation analysis was performed with genomic DNA extracted from all pre-and post-CT tumors using the AmpliChip p53 Test, a product which is currently under development at Roche Molecular Systems, Inc. The AmpliChip p53 Test is based on the microarray technology and is designed to re-sequence the coding region of the p53 gene and query for the presence of sequence alterations through comparative analysis of the hybridization pattern of a series of probes from sample DNA to wt reference DNA. Briefly, the test uses AmpliChip p53 microarrays, containing over 220,000 different oligonucleotide probes that are synthesized on a glass surface to analyze both sense and antisense strands of an amplified target DNA specimen. Upon PCR amplification and labeling of the p53 exons from specimen or reference samples, the biotin-labeled p53 amplicon fragments are hybridized to the AmpliChip p53 microarrays. The hybridized microarrays are washed and stained with a streptavidin-conjugated fluorescent dye (phycoerythrin) and are consecutively scanned by an Affymetrix GeneChip Scanner 3000Dx using a laser that excites the fluorescent label bound to the hybridized p53 amplicon fragments. The amount of emitted light is proportional to bound target DNA at each location on the probe microarray. Data analysis is performed by the GeneChip Operating Software (GCOS) and the AmpliChip p53 Data Analysis Software which uses p53 specific algorithms to analyze the intensity patterns of DNA samples, compare to the wt reference DNA sample and determine the sequence of p53 gene in the sample.
Results
Gene expression profiling. Our study included 6 patients with predominantly advanced stage, high-grade epithelial ovarian cancer, from whom both pre-and post-CT tumor specimens were available. The clinicopathological characteristics of these patients are presented in Table I . All 6 patients have undergone primary debulking surgery followed by standard platinum/ taxol combination therapy. They have displayed different time to recurrence intervals (TTR) after initial CT (7-17 months; Table I ) that are essentially below the median progressionfree interval (20-22 months) estimated for ovarian cancer patients receiving similar initial treatment (15, 16) . The period between the last CT treatment and the second-look laparotomy was quite variable for the 6 patients, ranging between 3-40 months (Table I) .
In order to look for molecular signatures of chemoresistant ovarian tumors, we performed pairwise gene expression comparison between pre-and post-CT tumor samples obtained from the same patient, as all microarray experiments were carried out in replicates. A subset of differentially expressed genes was selected from all microarray data by initial filtering on confidence at p=0.05, followed by filtering on expression level (≥2-fold). Using these selection criteria, we found 121 genes to be commonly up-regulated and 54 genes to be downregulated in the post-CT tumors, compared to that of the primary tumors. Functional classes of the 121 up-regulated genes mainly include metabolism (14%), signal transduction (13%), tumor progression (12%), chemoresistance (7%), regulation of transcription (7%), cell growth (6%), protein biosynthesis and modification (6%), transport (5%), cellular structural component (4%), development (3%), apoptosis (1%), DNA repair (1%); the remainder (21%) have unknown function. Table IIA shows list of selected genes that were up-regulated in the post-CT tumors. As seen from Table IIA,  there is substantial number of up-regulated genes with  previously shown implication in mechanisms of chemoresistance, including ovarian cancer chemoresistance (TOP2A,  ETV4, ABCF2, PRDX2, COX2, COX7B, MUC1, MT3,  MT2A), as well as genes linked with tumor progression and  ovarian malignancy (SCGB2A2, S100A9, YWHAE, SFN, Table I. Patient clinicopathological characteristics.  -----------------------------------------------------------------------------------------------------Patient  Age  HT  Grade  Stage  TTR  Period between last CT  LFU  (months)  and 2nd LAP (months)  -----------------------------------------------------------------------------------------------------VOA149  57  SPAC  3  IIIC  8  8  DOD  OV-111  65  SPAC  3  IV  13  13  DOD  OV-234  49  CCC  NA  IC  17  17  DOD  OV-86  63  SPAC  3  IIIC  9  40  LFU  OV-113  42  SPAC  2  IV  16  3  DOD  OV-118  41  SPAC  1  IIIC  5 12
HT, histological type; SPAC, serous papillary adenocarcinoma; CCC, clear cell carcinoma; CT, chemotherapy; TTR, time to recurrence following initial CT; LAP, laparotomy; LFU, lost from follow-up; DOD, died of disease; NA, not applicable. 
Selected down-regulated genes in the post-CT tumors Fold change Gene name Description LGALS3BP, TUBA4, AMY2B, PPIA, COX1, GRB2, CTSL). Several genes involved in negative regulation of cell proliferation (PPP2R4, H1F0, PBP, TP53I11) and DNA repair (APTX, UVRAG) were also found to be up-regulated. Fifty-four genes were subject to at least 2-fold downregulation in the post-CT tumors. Major classifications of these genes comprise immune response (15%), regulation of transcription (14%), metabolism (13%), signal transduction (11%), development (10%), tumor progression (8%), cellular structural component (7%), transport (6%), cellular growth (3%), and unknown function (13%). Table IIB shows list of selected genes that were down-regulated in the post-CT tumors. This list includes genes implicated in chemosensitivity (GRP, TRA1, ADPRTL1, TRF4-2), cell proliferation and cell cycle control (NGFRAP1, TPD52L1, TAX1BP1), tumor suppression and apoptosis (SMOC2, TIMP3, AXIN1, CASP4, P53SCV). Interestingly, several tumor (including ovarian tumor) markers (FHL2, S100B, PLAT, SERPING1, FMOD, CSF1R) were found to be down-regulated in the post-CT samples.
Supplemental data Table I shows the complete list of differentially expressed genes in the post-CT ovarian tumors as compared to that of the primary tumors.
Confirmation of the expression measurements.
To validate microarray results, we arbitrarily selected 13 up-regulated genes and quantified their expression by sqRT-PCR in the available pre-and post-CT tumor samples, Table III summarizes the gene expression measurements of all validated genes. We found that both methods (microarray analysis and sqRT-PCR) detected similar patterns for the 13 up-regulated genes selected for validation. Mean expression values were positive for all 13 genes and significantly positive (p≤0.05) for 8 of 13 genes.
Identification of two distinct pre/post-CT expression profiles: possible link with p53 mutation status and/or CT treatment regimens. Surprisingly, upon examination of the individual gene expression profiles (pre-and post-CT) of the 6 ovarian cancer patients studied we have detected two distinct types of gene expression profiles, unraveling the possible existence of two separate groups each including 3 patients: Group 1 including patients VOA149, OV-111 and OV-234, and Group 2 including patients OV-86, OV-113 and OV-118. This observation was further confirmed by cluster analysis. First, we selected a subset of candidate genes by filtering on signal intensity (2-fold) to eliminate genes with uniformly low expression or genes whose expression did not vary significantly across the samples, retaining 3,167 genes. One-way ANOVA parametric test (Welch t-test; variances not assumed equal) was further used to select discriminatory genes. t-tests with p-value cutoff of 0.005 selected 264 genes for which expression differed between the 2 groups. Clustering analysis based on the 264 gene list was performed using the standard Condition Tree algorithm provided in GeneSpring and revealed formation of two major cluster groups (Fig. 1) . The 264 gene list is presented in Supplemental data Table II .
One hundred and twenty-one genes from the 264-genes list were respectively up-regulated in Group 1 tumors and down-regulated in Group 2 tumors. Major classifications of these genes include regulation of transcription, protein biosynthesis, cell proliferation and metabolism. Genes downregulated in Group 1 tumors and up-regulated in Group 2 Table II . Continued. 
The above gene lists contain some additional genes with lower expression values (ranging between 1.5-to 2-fold), which are functionally relevant to tumor biology and response to treatment.
b The table contains selected references supporting the involvement of certain genes in mechanisms of chemoresistance and ovarian tumorigenesis.
tumors (143 genes) are mainly involved in signal transduction, regulation of transcription, immune response and inflammation, protein modification, metabolism and cell adhesion. Our data indicate the presence of some functional categories of differentially expressed genes that are specific for each of the two cluster groups (Table IV) .
We further checked the mutation status of the p53 gene in these tumor samples and performed more detailed analysis of the clinical charts of the six patients in order to find any parameters that could potentially explain their clustering. The p53 mutation analysis showed some differences between the groups, since two Group 1 tumors carried different p53 mutations, while two Group 2 tumors contained the wildtype p53 gene with the codon 72 polymorphism (Table V) . Interestingly, patient VOA149 had a mutation at codon 85 of the p53 gene only in the post-CT tumor sample, while the primary tumor contained the wild-type p53 allele, indicating that this mutation might be acquired during/after CT treatment. Analysis of different clinical parameters, including CA125 values, initial and residual tumor size, genetic predisposition, etc., did not displayed any significant differences between the two tumor groups (data not shown). The only substantial distinction between the patients from the two groups was the intensity of CT regimens between the two surgical inter- Table IV . Selected functional categories of differentially expressed genes (2-fold; p=0.005) that are specific for Group 1, or Group 2 post-CT ovarian tumors.
Cell proliferation DARS, RPL29, NACA, EIF3S6IP, RPL39, RPL23A, MRPL45, Protein biosynthesis MRPL43, RPL30, MRP63, MRPS27
Specific sets of genes down-regulated in Group 1 and up-regulated in Group 2 Gene symbol Function
Inflammation and immune response FLT3LG, DOK4, GALR3, GRIN1, SLA, GNA12, ABR, TRPV5, CBRC7TM_2, Signal transduction LOC90139, DRD1A, CBRC7TM_519, NTNG2, GPR14, GPR7, RAB6B COL3A1, CSPG2, ARHGAP9, NRXN2, DPT, BAIAP1
Cell adhesion Table III . Correlation of mRNA expression data from the training set with sqRT-PCR derived values. 
Mean value was calculated as the mean expression value for given marker in all pre-and post-CT tumor samples.
ventions (the primary cytoreductive surgery and the secondlook laparotomy). During this period, the patients from Group 1 have received only one CT regimen, while the Group 2 patients have been more heavily treated, receiving at least two CT regimens (Table V) .
Discussion
In this study we have used the microarray technology to examine gene expression profiles of ovarian tumor samples obtained from the same patient prior to, and following systemic CT. Such samples are quite uncommon since second-look laparotomy is a very rare practice in treatment of ovarian carcinomas, and obviously these cases refer to aggressive/ metastatic cancer. Indeed, screening of our ovarian tumor bank which currently comprises more than 600 ovarian tumor specimens allowed us to find paired tumor samples (pre-and post-CT) only from 5 patients, as we have obtained paired samples from one more patient from the ovarian tumor collection in the University of British Columbia. For each patient, we performed pairwise gene expression comparison between pre-and post-CT tumor samples in order to gain insight into global changes describing the chemoresistant phenotype. To our knowledge, similar expression analyses using paired ovarian tumor samples with common origin (obtained from the same patient) have not been yet performed. The rationale for this approach was 2-fold. First, we were able to compare gene expression profiles between primary and post-CT tumor samples with identical genetic background, thus avoiding any 'noise' due to individual's genetic variations. Second, after each cycle of cytotoxic CT, the 'log kill' effect leads to a significant reduction in the number of tumor cells that are sensitive to the administered therapy (17, 18) . Hence, tumor samples obtained following CT are mostly derived from intrinsic resistant clones and are likely to display molecular signatures associated with chemoresistance. However, we cannot exclude the possibility that some tumor cells that survive the treatment are likely to experience changes in gene expression that allow them to withstand the selective pressure of the drugs used (acquired chemoresistance).
Using our selection criteria (expression 2-fold at p=0.05), we observed that more than twice (121 of 175) genes had higher expression in the post-CT compared with the primary tumors. A similar imbalanced distribution has been observed for other CT-based gene sets, i.e., platinum resistance in 60 NCI cell lines (19) , in 7 gastric cell lines (20) , in taxol-resistant breast cancer specimens (21) , and also quite recently, in resistant compared with sensitive ovarian tumors (22) . Thus our data confirm previous findings that overexpression of discriminatory genes is more often associated with CT resistance than sensitivity (22) .
As expected, post-CT tumors displayed up-regulation of several genes with functional relevance to mechanisms of chemoresistance (Table IIA) . Notably, increased COX2 expression has been repeatedly associated with CT resistance in ovarian cancer patients (23, 24) . Another member from the same gene family, COX7B, was also found to be up-regulated in post-CT breast tumors as compared to primary breast tumors (25) . TOP2A gene overexpression has been formerly linked with mechanisms of chemoresistance (26) (27) (28) (29) , including ovarian cancer chemoresistance (22, 30, 31) . ETV4 (E1AF or PEA3) is a member of the Ets-related transcription factor family and has been associated with high rates of cell invasion in ovarian cancer (32, 33) . Platinum treatment has been reported to up-regulate ETV4 (34) and ETV4 gene expression was significantly increased in cisplatin-resistant ovarian carcinoma (35) . The ABCF2 protein is a member of the ABCF transporter superfamily and was found to be amplified in a chemoresistant ovarian cancer cells (36) . Moreover, Tsuda et al recently reported that ABCF2 expression significantly correlated with gene amplification and CT response in clear cell ovarian adenocarcinomas, possibly contributing to the chemoresistant phenotype of this ovarian cancer histotype (37) . PRDX2 has been known to be induced by various oxidative stimuli and to play an important protective role from oxidative damage (38) . Its expression was correlated with resistance to apoptosis induced by ionizing radiation or cisplatin (39-41), highlighting Table V . Individual CT treatment regimens and mutation status of the p53 gene in the tumor samples of the 6 ovarian cancer patients enrolled in the study. 
CT, adjuvant chemotherapy; LAP, laparotomy; TX, taxol; CP, carboplatin; TPT, topotecan; DOX, liposomal doxorubicin; WT, wild-type (non-mutated); (M), mutation; (P), polymorphism.
-
the potential clinical importance of PRDX2 in chemoand radiation-resistance in cancer. We have also observed some increase in MUC1, MT3 and MT2A gene expression (Table IIA) , which possibly contributes to the chemoresistant phenotype of the post-CT ovarian tumors. In parallel, some genes involved in chemosensitivity (GRP, TRA1, ADPRTL1, TRF4-2) were found to be down-regulated in the post-CT tumor specimens (Table IIB) .
Additionally, numerous genes that have been implicated previously in tumorigenesis and more specifically in ovarian tumorigenesis were found to be up-regulated in post-CT tumors (Table IIA) . For instance, S100A9 was found to be overexpressed in common cancers, including ovarian cancer (42). SFN gene expression and methylation status can characterize histological features of different types of ovarian cancer (43). ASS is an enzyme involved in the arginine biosynthesis as L-arginine represents the sole precursor for nitric oxide (NO) synthesis (44). NO enhances tumor initiation, promotion and progression, and it was suggested that argininedegrading enzyme therapy might be beneficial for cancer patients, including ovarian cancer patients (22) . TACC3 has been recently identified as a novel biomarker of ovarian cancer (45). SRA1 displayed significant up-regulation in serous ovarian tumors compared with other ovarian tumor types and normal ovary (46). Recent reports revealed that COX1 contributes to carcinoma development in the ovary through stimulation of prostanglandin E2 production and neovascularization (47,48) and thus represents a potential target for prevention and treatment of epithelial ovarian cancer (49).
All genes mentioned above provide targets for prospective investigations of intrinsic and/or acquired chemoresistance in ovarian cancer. Differences in RNA expression were confirmed by sqRT-PCR for a sample of genes.
Interestingly in post-CT tumor samples, the expression of some genes representing positive regulators of cell proliferation (NGFRAP1, TPD52L1, TAX1BP1) was suppressed, while several genes involved in negative regulation of cell proliferation (PPP2R4, H1F0, PBP, TP53I11) were found to be up-regulated (Table II) . This observation supports the concept that decreased proliferation state of tumor cells may be involved in the development of acquired chemoresistance (50-54).
Unexpectedly, assessment of the individual post-CT/ pre-CT gene expression profiles of the six patients enrolled in this study revealed the existence of two distinct expression signatures of chemoresistant tumors, which was further confirmed by cluster analysis. Using highly stringent selection criteria (2-fold differential gene expression; p-value cutoff of 0.005) we have identified a set of 264 discriminatory genes for which expression differed between the 2 groups (Fig. 1) . Thus, 121 genes from the 264-genes list were respectively upregulated in Group 1 tumors and down-regulated in Group 2 tumors, while 143 genes were found to be down-regulated in Group 1 tumors and correspondingly up-regulated in Group 2 tumors (Supplemental data Table I ). Some functional categories of differentially expressed genes displayed group specificity. For instance, genes with functional relevance to mechanisms of cell proliferation and protein biosynthesis were mostly upregulated in Group 1 tumors, while genes involved in inflammation and immune response, signal transduction and cell adhesion, were predominantly up-regulated in Group 2 tumors (Table IV) . Based on these data we could assume the existence of two subtypes of post-CT ovarian tumors with Group 2 tumors possibly displaying more chemoresistant/ aggressive phenotype than Group 1 tumors. Indeed, lower proliferation state, diminished protein biosynthesis and higher inflammation rates have been previously linked with chemoresitance (see above) and enhanced tumor progression (55,56). The more aggressive and chemoresistant phenotype of Group 2 tumors could be additionally sustained by higher expression of genes involved in signal transduction and cell adhesion, since it was shown that cell adhesion molecules not only define a tumor cell's adhesive repertoire, but also directly influence classic signal transduction pathways, thereby modulating the metastatic behavior of tumor cells (57).
The above observation for the existence of 2 subtypes of chemoresistant ovarian tumors with Group 2 tumors displaying the more chemoresistant/aggressive phenotype was further supported by analyses of some additional parameters, including the p53 gene mutation status and CT treatment regimens (Table V) . Thus, two of the Group 1 tumors carried different p53 missense mutations; however, p53 activity appears to have insignificant effect on response and survival to platinum-based treatment of ovarian tumors (58). In contrast, the p53 codon 72 polymorphism was found in two Group 2 tumors, and this polymorphism was previously linked with chemoresistance (59) and poor prognosis in ovarian cancer (60). Moreover, for the period between the two surgical interventions, Group 1 patients received only one CT regimen, while the Group 2 patients were more heavily treated, receiving at least two CT regimens which supports the suggestion for the more resistant phenotype of Group 2 tumors.
In summary, gene expression profiling has evidenced for specific expression signatures of chemoresistant post-CT ovarian tumors when compared with their paired primary tumors obtained from the same ovarian cancer patient. Our data suggest that intrinsic and acquired chemoresistant phenotypes of post-CT tumors may be attributed to the combined action of different factors implicated in mechanisms of chemoresistance, tumor invasion/progression and control of cell proliferation. Additionally, gene clustering analysis revealed the existence of two distinct expression signatures of chemoresistant tumors, which was further confirmed by assessment of some genetic and clinical parameters. It will be enlightening to carry out an extended study with more paired ovarian tumor samples in order to better understand the molecular mechanisms of ovarian cancer chemoresistance and the possible existence of different subtypes of chemoresistant tumors. This type of molecular profiling could have important clinical implications in resolving chemoresistance and the development of novel treatment strategies designed to prevent its emergence.
We are thankful to Dr Blake Gilks (Department of Pathology and Laboratory Medicine, Vancouver General Hospital) for sending us paired pre-/post-CT tumor samples and corresponding clinical data from one ovarian cancer patient. Supplementary Table I . List of differentially expressed genes (2-fold; p=0.05) in post-CT ovarian tumors compared to pre-CT tumors.
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